These results point to possible differences in degenerative mechanisms between recessive and dominant RP and suggest that PARP inhibition as a potential therapeutic strategy may need to be tested and tailored to individual disease genotypes. The gene discussed is PARP1; the disease is retinitis pigmentosa 1.